Status:
TERMINATED
Efficacy of Deutetrabenazine to Control Symptoms of Dysphagia Associated with HD
Lead Sponsor:
Fundacion Huntington Puerto Rico
Conditions:
Huntington Disease
Eligibility:
All Genders
21+ years
Phase:
PHASE1
Brief Summary
To determine the efficacy of deutetrabenazine to control symptoms of dysphagia associated with HD.
Detailed Description
The primary endpoint is the change in swallow function/dysphagia from baseline to maintenance therapy.
Eligibility Criteria
Inclusion
- Confirmed diagnosis of HD
- Symptoms of dysphagia
- Must be able to swallow tablets
Exclusion
- Other confounding diseases that affect swallowing
- Depression
- Hepatic impairment
- Renal impairment
- Dementia
Key Trial Info
Start Date :
January 21 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2023
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT04301726
Start Date
January 21 2022
End Date
September 1 2023
Last Update
February 27 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fundacion Huntington Puerto Rico, Inc. - Huntington's disease Clinic
San Juan, Puerto Rico, 00926